Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from grass pollen allergy
Latest Information Update: 22 Sep 2023
At a glance
- Drugs Phleum pratense cluster allergy immunotherapy ROXALL Medizin GmbH (Primary)
- Indications Allergic rhinitis; Allergic rhinoconjunctivitis
- Focus Therapeutic Use
- Acronyms CLUSTOID Grass Study
- Sponsors Roxall Medizin GmbH
Most Recent Events
- 20 Dec 2022 New trial record